0
0
8/25/22 at 3:58pm
Organization
Healthday.com
Author
Physician’s Briefing Staff
25 words
0
Comments
Olokizumab superior to placebo and noninferior to adalimumab in producing ACR20 response at 12 weeks
You are the first to view
https://consumer.healthday.com/olokizumab-tops-placebo-for-ra-patients-receiving-methotrexate-2657895099.html
Create an account
or login to join the discussion